Diabetes News You Can Use
Hypertension may influence CV risk regardless of BP threshold used
A study in The New England Journal of Medicine found that regardless of whether the threshold for hypertension was blood pressure of at least 140/90 mm Hg or 130/80 mm Hg, systolic and diastolic hypertension may influence the risk for adverse cardiovascular events, such as myocardial infarction, hemorrhagic stroke and ischemic stroke. Data on more than 1.3 million patients were included in the analysis.
Diabetes-associated increase in HF risk differs among men and women
A meta-analysis published in Diabetologia involving more than 12 million people found that women with type 1 diabetes had more than fivefold higher risk of developing heart failure compared with women who did not have diabetes, while HF risk among women with type 2 diabetes was almost doubled. Men with either type of diabetes also had higher risk of HF than men without diabetes, but the increase in risk was not as high as for women.
FDA declines to approve AZ drug for type 1 diabetes
The FDA issued a complete response letter to AstraZeneca declining its application for Farxiga, or dapagliflozin, to be used as a supplement to insulin in adult patients with type 1 diabetes that do not respond adequately to insulin alone. The company plans to meet with the agency to decide its next action.
CV risk tied to age, sex, ethnicity in type 2 diabetes
Researchers reported at the Heart in Diabetes conference that women with type 2 diabetes in the US had worse health outcomes, such as being less likely to receive cardiovascular drugs, having multiple hospitalizations and worse quality of life than men, while patients who received a diabetes diagnosis before age 40 had an up to 50% increased risk for combined renal and CV endpoints and renal death than those diagnosed later. Findings also revealed that blacks and Hispanic Americans had the lowest CVD health scores among women.
Study: Some type 1 diabetes patients may have monogenic diabetes
Researchers tested 1,019 individuals being treated for type 1 diabetes and found that a minority of them actually have monogenic diabetes, which may not require insulin treatment. Senior study author George King of the Joslin Diabetes Center said the findings, published in the Journal of Clinical Investigation, have clinical implications and they “are recommending that everyone under 18 who is diagnosed with type 1 diabetes be screened for monogenic diabetes, which is not being done at this time.”
The Diabetes Times (UK) (7/4)
Consumers travel to Canada to buy cheaper insulin
A caravan of patients with type 1 diabetes traveled from Minneapolis to London, Ontario, last week to buy insulin. The group of about 20 people collectively saved $15,000 to $20,000 for three months’ worth of supply, according to Nicole Smith-Holt, whose adult son died two years ago after rationing insulin due to the expense.
Pancreas size in pediatric type 1 diabetes affects exocrine function
In a comparison study conducted on 122 children, some with type 1 diabetes and some without the condition, investigators found that those with type 1 diabetes developed smaller transverse and longitudinal pancreatic areas, which could adversely affect exocrine function in these patients. Results of the research were published in the journal Diabetic Medicine.
FDA expands indication of Novo Nordisk’s Victoza
The FDA has approved Novo Nordisk’s Victoza, or liraglutide, injection for use in patients 10 to 17 years of age with type 2 diabetes. The drug was previously approved for adults with the condition.
Seeking Alpha (6/17)
Panel releases new time-in-range recommendations for CGM use
A panel convened by the Advanced Technologies & Treatments for Diabetes Congress issued new time-in-range recommendations for type 1 and type 2 diabetes patients using a continuous glucose monitoring device. The recommendations, presented at the American Diabetes Association annual meeting and published in Diabetes Care, cover most diabetes patients, pregnant or older patients or those at high hypoglycemia risk.
Medscape (free registration) (6/18)
Increased sleep duration tied to reduced cardiometabolic risk
Individuals who increased the duration of their sleep at night by 21 to 177 minutes experienced improved cardiometabolic health markers, including measures of insulin sensitivity and reduced levels of leptin and peptide tyrosine-tyrosine, as well as reductions in daily free sugar intake, overall appetite, cravings for sweet and salty foods and percentage of daily caloric intake from protein, according to a study in the Journal of Sleep Research. Findings were derived from a review of seven studies with a collective 138 participants.
10-02-2019 - 1:00 pm Daniel Drucker, MD
850 Republican St
Seattle, WA 98109
Senior Investigator, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada
Daniel Drucker, MD